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Abstract 
Background:  While there is a suggestion that self-reported tobacco smoking may be a risk factor 
for dementia, to date, it has not been possible to explore the thresholds at which this exposure 
elevates risk.  Accordingly, our aim was to relate cotinine, a biomarker of tobacco smoking, to risk 
of dementia death.  
Methods:  We pooled 14 prospective cohort studies that held data on cotinine (plasma or saliva), 
covariates, and death records.   
Results:  In the 33,032 study members (17,107 women) with salivary cotinine data, a mean duration 
of 8.3 years of follow-up gave rise to 135 deaths ascribed to dementia; while in 15,130 study 
members (7995 women) with plasma cotinine data, there were 119 dementia deaths during 14.3 
years of mortality surveillance.  After multiple adjustment, both plasma cotinine (hazard ratio per 
one standard deviation higher cotinine; 95% confidence interval: 1.29; 1.05, 1.59) and salivary 
cotinine (1.10; 0.89, 1.36) were positively related to dementia risk, with stronger effects for plasma.   
Conclusion:  Our finding that plasma cotinine was related to an elevated risk of dementia death 
warrants testing in studies with measures of disease onset as opposed to just mortality.   
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What is already known  
• In cohort studies, self-reported cigarette smoking reveals a positive relation with dementia risk. 
• In the absence of objective measurement of this health behaviour, it has not been possible to 
explore the thresholds at which this exposure elevates dementia risk. 
 
What this paper adds  
• To the best of our knowledge, this is the first study to utilise objective (cotinine) data to examine 
the smoking–dementia link.  
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Introduction 
It is well documented that dementia is, and will remain for the foreseeable future, a global public 
health priority.(1)  The fiscal, social and health consequences of dementia are profound.(1)  In the 
absence of effective treatments, much research attention has focused on primary prevention via the 
identification of modifiable risk factors which may be associated with the occurrence of dementia, 
its progression, and prognosis.(2)  Position statements and systematic reviews of the literature have 
suggested a role for selected nutritional factors, physical inactivity, certain somatic medical 
conditions, and cognitive training, although the evidence base, while voluminous, is 
inconclusive.(2)  
 
Cigarette smoking is another plausible modifiable risk factor.  Small scale, high resolution studies 
showing that smokers, relative to their non-smoking counterparts, have a greater degree of brain 
atrophy, and lower grey matter density in selected areas(3) has prompted a series of large, 
population-based investigations of the link between this health behaviour and dementia risk.  While 
these generally show that cigarette smokers typically experience higher rates of future dementia,(3, 
4) with the evidence being based exclusively on self-reported smoking data it has not been possible 
to explore the thresholds at which this exposure elevates risk.  Utilising objective markers of 
exposure to direct and indirect cigarette smoking, such as cotinine, would circumvent this problem 
but we are unaware of any such studies.  Accordingly, we carried out a pooling of raw data from 14 
longitudinal studies with information on cotinine and dementia.   
 
Methods 
We pooled individual-level data from 14 independent, geographically-representative, 
methodologically near-identical surveys of individuals living in private households conducted 
between 1994 and 2008 in the UK.(4-7)  Ethical approval for each survey was granted by local 
Research Ethics Committees, and study members provided informed consent.   
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Measurement of cotinine and covariates 
In 3 studies taking place before 1998 (Health Survey for England [HSE] 1994, 1996; and Scottish 
Health Survey [SHS] 1995) the assessment of cotinine was based on a sample of venous blood, 
whereas salivary cotinine was captured subsequently in 11 studies (HSE [1998-2004, 2007, 2008] 
and SHS [1996, 2003]).  All cotinine assays were performed by the same laboratory using standard 
gas chromatographic methods with a lower detection limit of 0.1 ng/ml.(8)  While plasma cotinine 
and salivary cotinine are strongly correlated, levels are typically higher in saliva to the extent that 
the two measures cannot be combined.(9)  Our covariates of socioeconomic status, frequency of 
alcohol consumption, and longstanding illness were self-reported using standard protocols.   
 
Ascertainment of dementia 
Study members were linked to national cause of death registers until 15
th
 February 2011 for HSE or 
31
st
 December 2009 for SHS.  Dementia was denoted by any mention of death from this disorder on 
certificates, as identified using codes 290.0 to 290.4, 294.9, 331.0 to 331.2 and 331.9 (for ICD-9) 
and codes F00, F01, F03, F09, G30 and G31 (for ICD-10).  In a cohort of Scottish individuals 
participating in a memory clinic who had gerontologist-confirmed dementia, almost three quarters 
of those who subsequently died had dementia recorded on their death certificate.(10)  This suggests 
the use of any mention of death from this disorder has sufficient validity for use in population-based 
studies.   
 
Data analyses  
We pooled the data for the 14 studies and fitted Cox proportional hazards models(11) to estimate 
hazard ratios with accompanying 95% confidence intervals for the association between each of the 
two indicators of cotinine and dementia death rates.  Initially, we adjusted hazard ratios for survey 
year, sex and age (linear and quadratic).  Subsequently, the confounding variables of socioeconomic 
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status, alcohol intake, and longstanding illness were added to the multivariable model.  Throughout 
our analyses we used calendar period as the time scale.   All analyses were computed using SAS 
(version 9.3). 
 
Results 
In the 33,032 study members (17,107 women) with salivary cotinine data, a mean duration of 8.3 
years of follow-up gave rise to 135 deaths ascribed to dementia; while in 15,130 study members 
(7995 women) with plasma cotinine data, there were 119 dementia deaths during 14.3 years of 
mortality surveillance.   
 
Both plasma cotinine and salivary cotinine were positively related to dementia risk, such that higher 
levels of exposure were associated with an elevated dementia rates (table 1).  The magnitude of 
these associations were markedly greater for plasma cotinine, with statistical significance apparent 
in people with a level of >200ng/ml (vs. 0-1.0:  age-, sex-, and study year-adjusted hazard ratio; 
95% confidence interval:  1.84; 1.02, 3.33).  While there was also a suggestion of a dose-response 
relationship across the plasma cotinine categories (p-valu  0.02), active rather than passive smoking 
appeared to be generating this gradient.  Controlling for covariates which included existing physical 
illness had little impact of the strength of these relationships.  Adding self-reported cigarette 
smoking to the multivariable model, however, essentially eliminated the age- and sex-adjusted 
relationship between plasma cotinine and dementia (>200.0 vs. 0-1.0ng/ml:  1.16; 0.45, 3.00).  By 
contrast, hazard ratio for current cigarette smoking remained elevated (vs. never smokers: 2.04; 
0.83, 5.05) even after adjustment for plasma cotinine, although statistical at conventional levels was 
not apparent.  
 
In sub-group analyses, we explored the issue of reverse causality such that unmeasured dementia at 
baseline – there was no cognitive testing in our studies – may have led to an elevation in the 
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prevalence of cigarette smoking, potentially due to the raised levels of psychological distress seen 
in people experiencing cognitive impairment.(12)  To do so, we dropped dementia deaths within the 
first 5 years of mortality surveillance and repeated our analyses (Supplemental Table 1).  With these 
exclusions – 24/119 of the dementia deaths in the plasma cotinine analyses and 37/135 of the 
dementia deaths in the salivary cotinine analyses occurred in the first 5 years of follow-up – the 
trend and hazard ratios in the plasma cotinine categories has strengthened somewhat while the 
hazard ratios for salivary cotinine are essentially unchanged.    
 
Discussion 
The main finding of this pooling of individual participant data from 14 prospective cohort studies 
was that plasma cotinine levels were related to a higher dementia risk in a dose-response manner, 
while the association with salivary cotinine was much weaker.  That adjustment for self-reported 
cigarette smoking eliminated the plasma cotinine–dementia association suggests that our assessment 
of plasma cotinine provides no additional value for the prediction of this disorder beyond self-
reported smoking behaviour.     
 
Study strengths and limitations 
The present study has some strengths, including the use of a biomarker of tobacco smoking rather 
than self-report, and the near full coverage of study members for mortality surveillance.  It is also 
not without its shortcomings.  The short half-life of cotinine means that it does have limitations in 
capturing longer term exposure to smoking.  While we have previously demonstrated that dementia 
death appears to be a valid indicator of dementia in population-based studies,(10) this health 
outcome does nonetheless combines disease incidence (aetiology) and survival from the disorder 
(prognosis).  Having comprehensive data on dementia incidence, which is problematic to capture 
except via extensive cognitive testing, would have greater utility when investigating the risk factors 
for this disorder.  Lastly, a low number of dementia deaths meant that we were not able to examine 
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the association between passive smoking and dementia by exploring cotinine–dementia links in 
self-declared in non-smokers. 
 
Existing literature and potential mechanisms 
While there are, to the best of our knowledge, no studies relating a biomedical marker of exposure 
to tobacco smoke and dementia risk, several investigators have characterised self-reports of this 
health behaviour in the context of both active and passive smoking.  As described, reviews of direct 
smoking generally reveal positive relationships with dementia risk.(2)  In studies which attempt to 
capture second-hand smoking via self-report there is also evidence of an increased risk of dementia 
although at rates which, as expected, appear to be lower than those seen in active smokers.(13)  In 
one of the few studies to have explored the link between biochemical markers of tobacco smoke and 
cognitive ability, itself a powerful risk factor for dementia, there was evidence that higher levels of 
salivary cotinine were associated with greater impairment.(14)   
 
That the cotinine–dementia gradient was robust to adjustment for selected confounding factors 
raises the possibility that direct mechanisms may be generating this association.  As indicated, 
imaging studies suggest that, compared with abstainers, smokers have a greater degree of brain 
atrophy, and lower grey matter density in selected areas.(3)  Other potential explanations include 
the observation that smoking exposure has a deleterious influence on the cardiovascular system, 
including increased coagulation of blood platelets, decreased coronary flow velocity reserves, 
accelerated atheroma genesis, and endothelial dysfunction.(15)  Endothelial dysfunction has been 
implicated in the reduced clearance of β-amyloid protein which is involved in the pathogenesis of 
Alzheimer's disease.(16) 
 
In conclusion, our finding that plasma cotinine was related to an elevated risk of dementia death 
warrants testing in studies with measures of disease incidence.   
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Table 1.  Association of plasma and salivary cotinine with death from dementia: pooling of 14 cohort studies 
 Plasma cotinine  Salivary cotinine 
Smoking status 
(Cotinine, ng/ml) 
Number  
at risk 
Dementia  
cases 
Hazard Ratio (95% CI)  Number 
at risk 
Dementia  
cases 
Hazard Ratio (95% CI) 
Model 1 Model 2  Model 1 Model 2 
          
Non-smokers  
(0-1.0) 
8543 76 1.0 (ref) 1.0 (ref)  21155 93 1.0 (ref) 
 
1.0 (ref) 
Passive smokers  
(1.1-15.0) 
2347 16 1.19 
(0.69, 2.06) 
1.07 
(0.62, 1.86) 
 4223 22 1.26 
(0.79, 2.01) 
1.23 
(0.77, 1.97) 
Active smokers, low 
intensity (15.1-200.0) 
1424 13 1.68 
(0.93, 3.05) 
1.58 
(0.87, 2.86) 
 2119  9 1.51 
(0.76, 2.99) 
1.47 
(0.74, 2.93) 
Active smokers, high 
intensity (>200.0) 
2816 14 1.84 
(1.02, 3.33) 
1.79 
(0.98, 3.27) 
 5535 11 1.19 
(0.63, 2.25) 
1.14 
(0.60, 2.17) 
          
P-value for trend - - 0.02 0.03  - - 0.27 0.35 
          
Per 1 standard 
deviation higher 
cotinine
a
 
15130 119 1.31 
(1.07, 1.61) 
1.29 
(1.05, 1.59) 
 33032 135 1.12 
(0.91, 1.38) 
1.10 
(0.89, 1.36) 
          
 
Model 1 - Hazard ratios are adjusted for age, age squared, sex, survey year.   
Model 2 - Hazard ratios are adjusted for age, age squared, sex, survey year, socioeconomic status, frequency of alcohol consumption, longstanding 
illness. 
a
Cotinine values were transformed to log (cotinine + 0.5) for this analysis to remove skewness  
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Supplemental Table 1. Association of plasma and salivary cotinine with death from dementia (excluding deaths in the first 5 years of follow-
up): pooling of 14 cohort studies
Plasma cotinine Salivary cotinine
Smoking status
(Cotinine, ng/ml)
Number
at risk
Dementia
cases
Hazard Ratio (95% CI) Number
at risk
Dementia
cases
Hazard Ratio (95% CI)
Model 1 Model 2 Model 1 Model 2
Non-smokers
(0-1.0)
7924 58 1.0 (ref) 1.0 (ref) 14052 68 1.0 (ref) 1.0 (ref)
Passive smokers
(1.1-15.0)
2197 13 1.29
(0.70, 2.37)
1.17
(0.63, 2.16)
3502 15 1.21
(0.69, 2.12)
1.19
(0.68, 2.10)
Active smokers, low
intensity (15.1-200.0)
1267 12 2.16
(1.15, 4.04)
2.07
(1.10, 3.88)
1522 8 1.81
(0.87, 3.77)
1.79
(0.85, 3.75)
Active smokers, high
intensity (>200.0)
2602 12 2.13
(1.11, 4.08)
2.17
(1.12, 4.19)
4093 7 1.02
(0.46, 2.25)
1.00
(0.45, 2.20)
P-value for trend - - 0.004 0.005 - - 0.41 0.47
Per 1 standard
deviation higher
cotininea
13990 95 1.43
(1.14, 1.78)
1.42
(1.14, 1.78)
23169 98 1.11
(0.87, 1.42)
1.09
(0.85, 1.40)
Model 1 - Hazard ratios are adjusted for age, age squared, sex, survey year.
Model 2 - Hazard ratios are adjusted for age, age squared, sex, survey year, socioeconomic status, frequency of alcohol consumption, longstanding
illness.
aCotinine values were transformed to log (cotinine + 0.5) for this analysis to remove skewness
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